Alan D. Horsager
Algemeen Directeur bij Olimmune, Inc.
Profiel
Alan D.
Horsager is currently the President & Chief Executive Officer at Olimmune, Inc. and the President, Chief Executive Officer & Director at Duet BioTherapeutics, Inc. He was previously the President at Scopus Biopharma, Inc. He received his undergraduate degree from the University of Washington and his doctorate from the University of Southern California.
Actieve functies van Alan D. Horsager
| Bedrijven | Functie | Begin |
|---|---|---|
Olimmune, Inc.
 Olimmune, Inc. Pharmaceuticals: MajorHealth Technology Part of Scopus Biopharma, Inc., Olimmune, Inc. develops immunotherapies for cancer treatment. The private company is based in Glendale, CA. The company was founded by Marcin Kortylewski. The CEO is Alan D. Horsager. Olimmune was acquired by Scopus Biopharma, Inc. on June 30, 2021. | Algemeen Directeur | - |
Duet BioTherapeutics, Inc.
 Duet BioTherapeutics, Inc. BiotechnologyHealth Technology Part of Scopus Biopharma, Inc., Duet BioTherapeutics, Inc. is a biotechnology company based in Pasadena, CA. The private company develops novel immunotherapies to overcome treatment-resistant cancers by selectively and simultaneously activating TLR9, which stimulates the body's immune system, and inhibiting STAT3, which counteracts critical tumor defense mechanisms. Duet is pursuing therapeutic candidates for the treatment of solid tumors and hematological malignancies using a distinct set of oligonucleotide inhibitors, including antisense, small-interfering RNA, and decoy technologies. Duet-101, the company's IND-ready lead candidate, combines CPG with a STAT3-inhibiting ASO and is being developed for the treatment of advanced solid tumors. The CEO of the company is Alan D. Horsager. | Algemeen Directeur | - |
Eerdere bekende functies van Alan D. Horsager
| Bedrijven | Functie | Einde |
|---|---|---|
| SCOPUS BIOPHARMA INC. | President | - |
Opleiding van Alan D. Horsager
| University of Washington | Undergraduate Degree |
| University of Southern California | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SCOPUS BIOPHARMA INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Olimmune, Inc.
Olimmune, Inc. Pharmaceuticals: MajorHealth Technology Part of Scopus Biopharma, Inc., Olimmune, Inc. develops immunotherapies for cancer treatment. The private company is based in Glendale, CA. The company was founded by Marcin Kortylewski. The CEO is Alan D. Horsager. Olimmune was acquired by Scopus Biopharma, Inc. on June 30, 2021. | Health Technology |
Duet BioTherapeutics, Inc.
Duet BioTherapeutics, Inc. BiotechnologyHealth Technology Part of Scopus Biopharma, Inc., Duet BioTherapeutics, Inc. is a biotechnology company based in Pasadena, CA. The private company develops novel immunotherapies to overcome treatment-resistant cancers by selectively and simultaneously activating TLR9, which stimulates the body's immune system, and inhibiting STAT3, which counteracts critical tumor defense mechanisms. Duet is pursuing therapeutic candidates for the treatment of solid tumors and hematological malignancies using a distinct set of oligonucleotide inhibitors, including antisense, small-interfering RNA, and decoy technologies. Duet-101, the company's IND-ready lead candidate, combines CPG with a STAT3-inhibiting ASO and is being developed for the treatment of advanced solid tumors. The CEO of the company is Alan D. Horsager. | Health Technology |
